Donavan to lead Siemens' Clinical Trial Business
Siemens Medical Solutions has chosen Hugh C. Donavan to be general manager of its new Clinical Trials Business, a program created to develop products that streamline the clinical trials process working with a number of Siemens technologies in addition to leveraging new and existing partnerships to build research efforts, Siemens said.
In particular, the Clinical Trials Business will emphasize two problem areas in its work, the identification and recruitment of eligible patients, as well as the data capture process.
Donavan has held vice president, global data management positions at Aventis Pharmaceuticals and Hoechst Marion Roussel. He has also worked on clinical trial analysis at a number of companies including Amgen Inc. and Searle Inc. Additionally, Donovan has been involved with several industry organization such as the Society for Clinical Data Management, where he was vice-president and chairman of the board of trustees, Siemens said.
In particular, the Clinical Trials Business will emphasize two problem areas in its work, the identification and recruitment of eligible patients, as well as the data capture process.
Donavan has held vice president, global data management positions at Aventis Pharmaceuticals and Hoechst Marion Roussel. He has also worked on clinical trial analysis at a number of companies including Amgen Inc. and Searle Inc. Additionally, Donovan has been involved with several industry organization such as the Society for Clinical Data Management, where he was vice-president and chairman of the board of trustees, Siemens said.